Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Rapport sur les actions

Capitalisation boursière : CN¥22.3b

Tianjin Pharmaceutical Da Ren Tang Group Résultats passés

Passé contrôle des critères 2/6

Tianjin Pharmaceutical Da Ren Tang Group has been growing earnings at an average annual rate of 10.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 5.1% per year. Tianjin Pharmaceutical Da Ren Tang Group's return on equity is 14.3%, and it has net margins of 11.6%.

Informations clés

10.9%

Taux de croissance des bénéfices

10.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie10.9%
Taux de croissance des recettes5.1%
Rendement des fonds propres14.3%
Marge nette11.6%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Recent updates

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Oct 27
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Oct 08
Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Ventilation des recettes et des dépenses

Comment Tianjin Pharmaceutical Da Ren Tang Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

SHSE:600329 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 248,0409322,621197
30 Jun 248,0999222,575179
31 Mar 248,0509152,503184
31 Dec 238,2229872,527185
30 Sep 238,4799912,562147
30 Jun 238,5631,1162,551150
31 Mar 238,5141,0632,490158
31 Dec 228,2498622,356153
30 Sep 227,1188371,910159
30 Jun 227,0427751,932150
31 Mar 226,9707561,929151
31 Dec 216,9087691,935161
30 Sep 216,9998461,911168
30 Jun 216,9548011,839169
31 Mar 216,7757051,843158
31 Dec 206,6046621,821149
30 Sep 206,7736571,934128
30 Jun 206,7516022,054126
31 Mar 206,8966052,126133
31 Dec 196,9946262,194133
30 Sep 196,8476062,174126
30 Jun 196,7805952,106118
31 Mar 196,4975782,043102
31 Dec 186,3595622,004101
30 Sep 186,0845172,01290
30 Jun 185,8145121,94387
31 Mar 185,8235161,82199
31 Dec 175,6894761,73379
30 Sep 175,7474331,74044
30 Jun 175,9524431,74829
31 Mar 176,0814381,7210
31 Dec 166,2434241,6920
30 Sep 166,8454671,5920
30 Jun 166,9974711,5640
31 Mar 167,1044521,6220
31 Dec 157,0814511,6330
30 Sep 157,0264361,7240
30 Jun 157,1143981,7450
31 Mar 157,1563751,7510
31 Dec 147,0873581,7050
30 Sep 146,6213721,6130
30 Jun 146,2673611,5550
31 Mar 146,1133361,5050
31 Dec 136,0103521,5080

Des revenus de qualité: 600329 has high quality earnings.

Augmentation de la marge bénéficiaire: 600329's current net profit margins (11.6%) are lower than last year (11.7%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: 600329's earnings have grown by 10.9% per year over the past 5 years.

Accélération de la croissance: 600329's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 600329 had negative earnings growth (-5.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).

Rendement des fonds propres

ROE élevé: 600329's Return on Equity (14.3%) is considered low.

Rendement des actifs

Rendement des capitaux employés

Découvrir des entreprises performantes dans le passé

7D

1Y

7D

1Y

7D

1Y